AFM
ENZ

Anson Funds Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Anson Funds Management’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-231,094
Closed -$321K – 220
2023
Q4 		$321K Buy
+231,094
New +$306K 0.04% 141

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Anson Funds Management's ENZ Position: Q1 2024 in Review

Anson Funds Management sold out of Enzo Biochem, Inc. (ENZ) in Q1 2024, closing a stake of 231,094 shares — an estimated $321K sold.

Anson Funds Management first reported a position in ENZ in Q4 2023 and held it in 1 quarter. The position peaked at $321K in Q4 2023. 41 funds tracked by Wall St. Rank hold ENZ as of Q1 2024.

  • Anson Funds Management reported no remaining Enzo Biochem, Inc. position as of Q1 2024 after selling out during the quarter.
  • Anson Funds Management sold 231,094 Enzo Biochem, Inc. shares in Q1 2024, an estimated $321K.
  • Anson Funds Management first reported a position in Enzo Biochem, Inc. in Q4 2023 and held it in 1 quarter.
  • Anson Funds Management's Enzo Biochem, Inc. position peaked at $321K in Q4 2023.
  • 41 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2024.

Based on Anson Funds Management's 13F filing for Q1 2024, filed 14 May 2024.